Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.47 |
| ▸ | HSD11B1 known ✓ | P28845 | 3/20 | 0.47 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | UQCRB | P14927 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196750 | 0.98 | ALDH1A1 (0.61) | ALDH1A1LMNAGAAUQCRBTSHR | |
| Ammonia Solution, Strong SCHEMBL27721989 | 0.95 | ALDH1A1 (0.59) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL25384264 | 0.91 | ALDH1A1 (0.55) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL2950033 | 0.91 | ALDH1A1 (0.55) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL16563156 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNAGAAUQCRBTSHR | |
| Ammonia Solution, Strong SCHEMBL25386856 | 0.90 | ALDH1A1 (0.53) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL16563244 | 0.88 | ALDH1A1 (0.53) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL28852092 | 0.88 | ALDH1A1 (0.52) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL16563158 | 0.88 | ALDH1A1 (0.52) | ALDH1A1LMNAGAAUQCRBTSHR | |
| SCHEMBL25385943 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAGAAUQCRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218193-A | 3- hydroxyquinazoline -2,4 (1H, 3H)-diketone derivative and the preparation method and application thereof | 山东大学 | 2019-09-10 | — | — | CN | disclosed |
| CN-106103439-B | 2,7- diaza spiro [3.5] nonane compound | 瑞敏德股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-107266425-A | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists | 坎莫森特里克斯公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-104520288-B | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | 坎莫森特里克斯公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-106103439-A | 2,7 diaza spiros [3.5] nonane compound | 瑞敏德股份有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-103476752-B | Substituted aromatic series sulphur compound and using method thereof | 赛福伦公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105601622-A | 1-oxo/acylated-14-acylated oridonin derivative and preparation method as well as application thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD | 2016-05-25 | — | — | CN | disclosed |
| CN-103002735-B | Modulators of 5-ht receptors and methods of use thereof | ABBVI CO | 2015-05-20 | — | — | CN | disclosed |
| CN-104168958-A | Diaryl sulfonamides useful for the treatment of inflammation and cancer | KANCERA AB | 2014-11-26 | — | — | CN | disclosed |
| CN-103002735-A | Modulators of 5-ht receptors and methods of use thereof | ABBVI CO | 2013-03-27 | — | — | CN | disclosed |
| CN-1867338-A | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER PROD INC (US) | 2006-11-22 | — | — | CN | disclosed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | disclosed |
| CN-1678306-A | -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases | BOEHRINGER INGELHEIM PHARMA (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1671386-A | Substituted anilinic piperidines as MCH selective antagonists | LUNDBECK & CO AS H (DK) | 2005-09-21 | — | — | CN | disclosed |
| CN-1655780-A | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | CN | disclosed |
| CN-1556702-A | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | — | 2004-12-22 | — | — | CN | disclosed |
| CN-1549714-A | Aminoisoxazole derivatives active as kinase inhibitors | — | 2004-11-24 | — | — | CN | disclosed |
| CN-1350452-A | Preventive or therapeutic drugs for diabetes | SHIONOGI & CO (JP) | 2002-05-22 | — | — | CN | disclosed |
| CN-1295677-A | Method and apparatus for accelerated orthokeratology | EASTA PHARMACEUTICALS INC (US) | 2001-05-16 | — | — | CN | disclosed |
| CN-1058880-A | The sulfoneoxime ester compound of tool Fungicidally active | DU PONT (US) | 1992-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | GAA 791/4885CA2 293/4885HSD11B1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.